Phase 3 Trial Testing Aromasin-Chidamide Combo for Advanced Breast Cancer Meets Primary Goal
News
Adding investigational therapy chidamide to Aromasin (exemestane) significantly delayed disease progression or death in patients with advanced breast cancer, results from a Phase 3 trial show. This means that the pivotal trial (NCT02482753) has ... Read more